SCHEMBL4112929

SCHEMBL4112929

CCc1ccc(NC(=O)Nc2ccc(O)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.69
MAOA P21397 1/20 0.60
MAOB P27338 1/20 0.60
KMT2A Q03164 8/20 0.59
MEN1 O00255 7/20 0.59
NPC1 O15118 6/20 0.59
MAPT P10636 5/20 0.59
POLB P06746 3/20 0.59
GAA P10253 3/20 0.59
USP2 O75604 2/20 0.59
ALOX15 P16050 2/20 0.59
HSD17B10 Q99714 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TP53 P04637 1/20 0.59
HTT P42858 1/20 0.59
ALDH1A1 P00352 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
APAF1 O14727 1/20 0.59
HPGD P15428 1/20 0.59
ALOX12 P18054 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113855 0.92 RAB9A (0.79) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL4112392 0.85 RAB9A (0.69) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL4112384 0.85 RAB9A (0.69) RAB9AMAOAMAOBKMT2AMEN1
SCHEMBL4112512 0.85 RAB9A (0.69) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL4112221 0.84 RAB9A (0.63) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL3166771 0.84 SMN1; SMN2 (0.69) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL16610194 0.84 DEGS1 (0.61) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL11327346 0.83 MAOA (0.82) RAB9AMAOAMAOBKMT2AMEN1
SCHEMBL4117248 0.83 RAB9A (0.67) RAB9AKMT2AMEN1NPC1MAPT
SCHEMBL4117952 0.83 RAB9A (0.67) RAB9AKMT2AMEN1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20160244462-A1 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-08-25 US disclosed
US-20160244462-A1 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-08-25 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 RAB9A 815/4885MAOA 557/4885MAOB 430/4885
US-20160244462-A1 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF XDH, DHFR, G6PD RAB9A 3424/4885MAOA 1696/4885MAOB 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.